antibody therapies Archives
Study identifies monoclonal antibodies that may neutralize many norovirus variants
Jul. 16, 2021—Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.
Combination antibody therapies should retain effectiveness against emerging COVID-19 variants: study
Jun. 22, 2021—Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature.
Therapeutic antibodies for hantavirus
May. 24, 2021—Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential.
VUMC team’s COVID-19 research featured on “60 Minutes”
Apr. 12, 2021—James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured Sunday on a CBS News 60 Minutes segment titled “The Last Pandemic.”
Crowe receives SEC Faculty Achievement Award
Apr. 12, 2021—James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.
U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC
Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
More than 1,000 receive antibody infusions for COVID-19 at VUMC
Feb. 10, 2021—As of Feb. 1,065 outpatients have received antibody infusions since the clinic opened on Nov. 18. Clinic officials estimated that the infusions have prevented about 70 patients from developing severe COVID-19 illness requiring hospitalization or emergency department evaluation.
Clinic uses new weapon to treat high-risk COVID patients
Dec. 17, 2020—Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Researchers developing potential coronavirus antibody therapies
Mar. 23, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Antibody mixture may help block Ebola virus infection
Feb. 6, 2020—A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.
Antibody isolated at VUMC found to halt dengue virus
Jan. 23, 2020—Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.
